Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles
- 7 February 2014
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 34 (5), 668-671
- https://doi.org/10.1111/liv.12467
Abstract
Hepatitis C infection is an important problem in inner city neighbourhoods, which suffer from multiple health disparities. Important factors in this population include alcoholism and substance abuse, mental illness and homelessness, which may be combined with mistrust, poor health literacy, limited access to healthcare and outright discrimination. Systemic barriers to effective care include a lack of capacity to provide comprehensive care, insufficient insurance coverage, poor coordination among caregivers and between caregivers and hospitals, as well as third party payers. These barriers affect real world treatment effectiveness as opposed to treatment efficacy, the latter reflecting the world of clinical trials. The components of effectiveness include efficacious medications, appropriate diagnosis and evaluation, recommendation for therapy, access to therapy, acceptance of the diagnosis and its implications by the patient and adherence to the recommended therapy. Very little attention has been given to assisting the patient to accept the diagnosis and adhere to therapy, i.e. care coordination. For this reason, care coordination is an area in which greater availability could lead to greater acceptance/adherence and greater treatment effectiveness.This publication has 26 references indexed in Scilit:
- Hepatitis C Virus Testing of Persons Born During 1945–1965: Recommendations From the Centers for Disease Control and PreventionAnnals of Internal Medicine, 2012
- Miles to Go before We SleepJournal of Health and Social Behavior, 2012
- Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008Journal of Hepatology, 2011
- The end of the beginning for hepatitis C treatmentJournal of Hepatology, 2011
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus InfectionThe New England Journal of Medicine, 2011
- Perspective: Test and treat this silent killerNature, 2011
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2011
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002Annals of Internal Medicine, 2006